Floatz logo

BUSULFANUM

Disease Related To Hematopoietic Stem Cell Transplant

Institute of Hematology & Blood Diseases Hospital, ChinaSmall moleculePhase 3Active
BBB
74/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
66/ 100
Competitive Position
89/ 100

Competitive context

54 Active assets in the Disease Related To Hematopoietic Stem Cell Transplant cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
The First Affiliated Hospital of Soochow University
Phase 3BBB
Nivestim
National Cancer Institute (NCI)
Phase 2/3BBB
Rituximab
M.D. Anderson Cancer Center
Phase 2BBB
Decitabine
Chinese PLA General Hospital
Phase 4BBB
TACROLIMUS
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3BB

View all 50 →

Same molecule, other indications

BUSULFANUM is also rated in:

myelodysplastic/myeloproliferative neoplasmActive
BBB
Indicative · Phase 2/3
76 / 100
View asset →
graft versus host diseaseActive
BBB
Indicative · Phase 4
74 / 100
View asset →
Fanconi anemiaActive
BBB
Indicative · Phase 2/3
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →